Tempest Q3 net loss $6.8M; TPST-1120 shows superiority in liver cancer; cash runway into 2025

Tempest Therapeutics, Inc.

2023-Q3 EPS reported -$1.57

Net loss $6.8M ($0.48/share) vs $8.9M ($0.66) in Q3 2022; R&D expense fell to $4.2M from $6.0M.
Cash $11.1M at Sep 30; after $23.9M ATM net proceeds, preliminary cash $32.8M extending runway into 2025.
TPST-1120 triplet arm cORR 30% vs 13.3% control; median PFS 7 mo vs 4.27 mo (HR 0.7); median OS not reached vs 15.1 mo (HR 0.59).
Plan to advance TPST-1120 into registrational study in first-line HCC, likely with a partner.
Adopted limited-duration stockholder rights plan on Oct 10, 2023 to deter hostile accumulation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported the nine months ended September 30, 2023 results: net income $22.0 million, EPS $1.57 per share.

Period: the nine months ended September 30, 2023
Net income: $22.0 million
EPS: $1.57 per share
Result: reported results

Exact text from the filing

Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income $6.8 million, EPS $0.48 per share.

Period: the quarter ended September 30, 2023
Net income: $6.8 million
EPS: $0.48 per share
Result: reported results

Exact text from the filing

Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.